MENU
+Compare
FMED
ETF ticker: NASDAQ
AS OF
Apr 23 closing price
Price
$23.02
Change
+$0.43 (+1.90%)
Net Assets
48.12M

FMED stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for FMED with price predictions
Apr 22, 2025

FMED saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for FMED moved out of overbought territory on April 22, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 21 similar instances where the indicator exited the overbought zone. In of the 21 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FMED entered a downward trend on April 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FMED's RSI Indicator exited the oversold zone, of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on FMED as a result. In of 31 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FMED just turned positive on April 15, 2025. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in of 16 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 107 cases, the price rose further within the following month. The odds of a continued upward trend are .

FMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 40.98B. The market cap for tickers in the group ranges from 498.6M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is STOK at 498.6M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 38%. For the same ETF, the average monthly price growth was 25%, and the average quarterly price growth was 122%. DYN experienced the highest price growth at 38%, while AGL experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 1%. For the same stocks of the ETF, the average monthly volume growth was -40% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 66
Price Growth Rating: 67
SMR Rating: 76
Profit Risk Rating: 77
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com